In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|August 12, 2021
Veraxa and Indivumed Collaborate on Development of Precision Oncology Antibody Drugs
Author(s)BioPharm International Editors
Veraxa and Indivumed will work together to develop colorectal antibody drugs.
Advertisement
Veraxa Biotech GmbH, Heidelberg, and Indivumed GmbH, Hamburg, announced that they will work together on the discovery and development of modulatory and functional antibodies against several targets relevant for colorectal cancer.
The targets were identified by Indivumed’s discovery solution platform nRavel. Veraxa will use its microfluidic technology to screen antibodies with modulatory function on complex signal proteins like GPCRs or ion channels. Antibody development and commercialization will be done by Indivumed subsidiary Ix Therapeutics.
“The high quality of data and the artificial intelligence tools that Indivumed utilizes means that we can be more confident in the validity of the targets,” said Christoph Antz, CEO of Veraxa, in a Induvimed press release from August 10, 2021. “With our technology, we can move rapidly into the development of functional antibodies that have the potential to serve as new therapeutics.”
“Having thousands of patient cases complete with comprehensive multi-omics and clinical data coupled with the advanced AI capabilities of nRavel gives us the ability to derive novel insights in just a short period of time,” said Hartmut Juhl, founder and CEO of Indivumed, in the press release. “As we continue to uncover additional targets, having a partner like Veraxa who can develop functional antibodies in an accelerated manner is critical to our ability to discover new possibilities for cancer treatment in the shortest-possible time and fight this disease.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5